TG Therapeutics Flashes An Early Buy Signal — What Drove The Bullish JumpInvestors Business Daily • 06/03/26
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)GlobeNewsWire • 06/03/26
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare ConferenceGlobeNewsWire • 06/02/26
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in ImmunologyGlobeNewsWire • 06/01/26
TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 OutlookSeeking Alpha • 05/28/26
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE TrialGlobeNewsWire • 05/27/26
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual MeetingGlobeNewsWire • 05/26/26
Multiple Sclerosis-Focused Biotech Quadruples Its Profit, Raises Sales ForecastInvestors Business Daily • 05/21/26
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 ViewZacks Investment Research • 05/07/26
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceGlobeNewsWire • 05/06/26
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business UpdateGlobeNewsWire • 04/30/26
TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 04/27/26
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster OutlookSeeking Alpha • 04/19/26
TGTX Completes Enrollment in Phase III Study on Subcutaneous BriumviZacks Investment Research • 04/16/26
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVIGlobeNewsWire • 04/15/26
TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting DownsideSeeking Alpha • 03/31/26
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 MillionGlobeNewsWire • 03/19/26
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock DropThe Motley Fool • 03/16/26
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple SclerosisGlobeNewsWire • 03/09/26